Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse

Abstract

Background:

Accumulating data highlight proinflammatory processes leading to MS relapses. Whether anti-inflammatory mechanisms are concomitantly activated is unclear. The ectonucleotidase CD39 has been described as a novel T regulatory cell (Treg) marker. The purpose of this study was to explore whether regulatory mechanisms are activated during MS relapses and reinforced by intravenous methylprednisolone (ivMP).

Methods:

Blood samples were collected from stable and relapsing MS patients and healthy controls. We used FOXP3 methylation-specific qPCR and CD4⁺CD25^highFOXP3⁺ analysis to quantify Tregs. Cytokine mRNA expression levels were measured in peripheral blood mononuclear cells (PBMCs) and in CD4⁺ T cells. CD39 expression was determined by flow cytometry in monocytes, NK, T and B cells. CD39 enzymatic activity was assessed by ATP luminometry.

Results:

The proportion of Tregs was similar in relapsing MS patients and healthy controls. CD39 mRNA level was higher in PBMCs of relapsing MS patients than in controls. The proportion of CD39-expressing Tregs was higher in MS patients. IvMP decreased the overall proportion of Tregs while it increased CD39 mRNA levels, the proportions of CD39-expressing Tregs and monocytes as well as CD39 ectonucleotidase activity.

Conclusions:

Our data suggest that immunoregulatory mechanisms are ongoing in MS patients, particularly during relapses, and strengthened by ivMP.

Keywords

Multiple sclerosis CD39 regulatory T cells corticosteroids relapse immunoregulation

Get full access to this article

View all access options for this article.

References

Muls

Jnaoui

Dang

. Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. J Neuroimmunol 2012; 243: 73–80.

Matusevicius

Kivisakk

. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101–104.

Tzartos

Friese

Craner

. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172: 146–155.

Viglietta

Baecher-Allan

Weiner

. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971–979.

Baron

Floess

Wieczorek

. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37: 2378–2389.

Gandhi

Kumar

Burns

. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 2010; 11: 846–853.

Borsellino

Kleinewietfeld

Di Mitri

. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225–1232.

Rudick . Multiple sclerosis therapeutics. London: Martin Dunitz, 1999, p.574.

Dodero

Carniti

Raganato

. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: Posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009; 113: 4771–4779.

10.

Wang

Long

. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2011; 234: 155–160.

11.

Steinman

. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 2014; 32: 257–281.

12.

Brucklacher-Waldert

Stuerner

Kolster

. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009; 132: 3329–3341.

13.

Gonsette

. Self-tolerance in multiple sclerosis. Acta Neurol Belg 2012; 112: 133–140.

14.

Praksova

Stourac

Bednarik

. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. J Neurol Sci 2012; 319: 18–23.

15.

Serpero

Filaci

Parodi

. Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J Neuroimmune Pharmacol 2013; 8: 1106–1113.

16.

Haas

Hug

Viehover

. Reduced suppressive effect of CD4+CD25^high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35: 3343–3352.

17.

Huan

Culbertson

Spencer

. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005; 81: 45–52.

18.

Zheng

Josefowicz

Chaudhry

. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010; 463: 808–812.

19.

Feger

Luther

Poeschel

. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007; 147: 412–418.

20.

Braitch

Harikrishnan

Robins

. Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurol Scand 2009; 119: 239–245.

21.

Sbiera

Dexneit

Reichardt

. Influence of short-term glucocorticoid therapy on regulatory T cells in vivo. PLoS One 2011; 6: e24345.

22.

Sionov

Cohen

Kfir

. Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis. J Exp Med 2006; 203: 189–201.

23.

Wüst

van den Brandt

Tischner

. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol 2008; 180: 8434–8443.

24.

Martinon

Mayor

Tschopp

. The inflammasomes: Guardians of the body. Annu Rev Immunol 2009; 27: 229–265.

25.

Fletcher

Lonergan

Costelloe

. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009; 183: 7602–7610.

26.

Dalla Libera

Di Mitri

Bergami

. T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS One 2011; 6: e21386.

27.

Peelen

Damoiseaux

Smolders

. Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse. J Neuroimmunol 2011; 240–241: 97–103.

28.

Bielefeld

Lee

Riddick

. Regulation of aryl hydrocarbon receptor expression and function by glucocorticoids in mouse hepatoma cells. Drug Metab Dispos 2008; 36: 543–551.

29.

Collison

Workman

Kuo

. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566–569.

30.

Mascanfroni

Yeste

Vieira

. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol 2013; 14: 1054–1063.

31.

Batten

. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006; 7: 929–936.

32.

Langrish

Chen

Blumenschein

. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233–240.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.81 MB

0.09 MB

0.06 MB